Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF NOVEMBER 08, 2006 FBO #1808
SOURCES SOUGHT

B -- Production of Experimental Virus Vaccines

Notice Date
11/6/2006
 
Notice Type
Sources Sought
 
NAICS
325414 — Biological Product (except Diagnostic) Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 10401 Fernwood Drive, Suite 2NE70, MSC 4811, Bethesda, MD, 20817, UNITED STATES
 
ZIP Code
00000
 
Solicitation Number
Reference-Number-NIAID-DIR-07-49
 
Response Due
11/21/2006
 
Description
The National Institute of Allergy and Infectious Diseases, Division of Intramural Research, seeks Capability Statements from qualified sources able to provide the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to prepare suspensions of viruses which have been shown by evaluation in vitro and in vivo to be promising candidates for use in immunoprophylaxis of human diseases. These virus suspensions, which are intended for evaluation in volunteers, shall be prepared using current Good Manufacturing Practices (cGMPs) and in facilities which meet FDA standards for preparation of live virus vaccines to be tested in Phase 1 and 2 clinical studies as described in the most current Code of Federal Regulations. In addition, suspensions of wild type viruses may also be prepared, which are needed for evaluation of effectiveness of immunoprophylaxis. These suspensions of vaccine or wild type virus shall be safety tested for use in human subject studies as required by the FDA. It is estimated that eight to ten virus suspensions will be made annually, and that one cell line will be qualified every other year. Potential offerors must be able to prepare the following virus suspensions and associated services as requested by the project Officer: Paramyxoviruses, Rotavirus, Hepatitis, Dengue viruses, Flavivirus chimeric viruses, Caliciviruses, and Influenza Viruses. Offerors must be capable of delivering the materials five months from the date of the receipt of seed viruses and avoid using animal-derived materials in vaccine manufacture whenever possible. Offerors must produce and qualify cell lines as directed by the NIAID Project Officer for use by NIAID staff and by the contractors in the production of viruses to be administered to humans or for other uses directed by the Project Officer. Virus vaccines and cell lines produced and qualified for use under this contract will be considered government-owned materials. Interested parties must provide a capability statement which demonstrates and documents that the offeror: has professional and technical personnel with extensive experience in the preparation of suspension of viruses, including wild type viruses, and possesses the necessary facilities to accomplish the work herein described, or the ability to obtain these. This announcement is not a request for proposals but an attempt to survey the market for potential sources. Capability statements, including offeror's business size, must be submitted to Ivan Hernandez at ihernandez@niaid.nih.gov on or before November 21, 2006.
 
Place of Performance
Address: Bethesda, MD
Zip Code: 20817
Country: UNITED STATES
 
Record
SN01176694-W 20061108/061106220210 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.